These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 13057308)

  • 1. [The passage of intravenously injected iron from the blood stream].
    OVERKAMP H
    Z Gesamte Exp Med; 1952; 120(1):86-95. PubMed ID: 13057308
    [No Abstract]   [Full Text] [Related]  

  • 2. [The behavior of intravenously administered iron in the organism].
    LINTZEL W
    Arztl Forsch; 1953 Mar; 7(3):I/134-6. PubMed ID: 13065190
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intravenous iron].
    DUFRESNE RR
    Union Med Can; 1952 Jun; 81(6):697-8. PubMed ID: 13005802
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tolerance of intravenous iron application].
    GOLDECK H; REMY D; MEYER F
    Arztl Wochensch; 1952 May; 7(21):489-90. PubMed ID: 14952397
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron in hematology: Danger with IV iron: Real or perceived?
    Auerbach M
    Am J Hematol; 2014 Jun; 89(6):664. PubMed ID: 24639085
    [No Abstract]   [Full Text] [Related]  

  • 6. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.
    Alan Brookhart M; Li X; Kshirsagar AV
    Semin Dial; 2017 Jan; 30(1):25-27. PubMed ID: 27766683
    [No Abstract]   [Full Text] [Related]  

  • 7. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.
    Wish JB
    Semin Dial; 2017 Jan; 30(1):20-22. PubMed ID: 27679413
    [No Abstract]   [Full Text] [Related]  

  • 8. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.
    Agarwal R
    Semin Dial; 2017 Jan; 30(1):22-25. PubMed ID: 27678472
    [No Abstract]   [Full Text] [Related]  

  • 9. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.
    Fishbane S
    Semin Dial; 2017 Jan; 30(1):27-29. PubMed ID: 27687015
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.
    Besarab A; Szczech L
    Semin Dial; 2017 Jan; 30(1):29-31. PubMed ID: 27699882
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous iron therapy.
    VARIAVA NS
    Antiseptic; 1952 Mar; 49(3):210-7. PubMed ID: 14934073
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intravenous iron therapy].
    Med Contemp; 1952 May; 70(5):299-301. PubMed ID: 14956388
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.
    Toblli JE; Cao G; Olivieri L; Angerosa M
    Nephrol Dial Transplant; 2010 Nov; 25(11):3631-40. PubMed ID: 20488820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experiences with intravenous iron therapy].
    SELIGER H
    Ther Ggw; 1952 Feb; 91(2):55-7. PubMed ID: 14922346
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous iron therapy with ferrum injectabile Vitis].
    PRIBILLA W
    Medizinische; 1952 Jun; 2():53-6. PubMed ID: 14940483
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
    Daniilidis A; Panteleris N; Vlachaki E; Breymann C; Assimakopoulos E
    J Obstet Gynaecol; 2018 May; 38(4):443-447. PubMed ID: 29057687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma iron levels after the intravenous administration of different iron preparations.
    NISSIM JA
    J Physiol; 1952 Dec; 118(4):63P-64P. PubMed ID: 13023666
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.